Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ: CRNX )

36.17 -2.81 (-7.21%)
Streaming Delayed Price Updated: 2:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Shares of Crinetics Pharmaceuticals Are Jumping Monday
The biotech company reported positive phase 3 trial results. 
Via The Motley Fool
Gold Edges Higher; Virco Manufacturing Shares Surge After Q2 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 80 points on Monday. The Dow traded up 0.40% to 34,715.88 while the NASDAQ rose 0.58% to 13,841.50. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Near the Top of Equities by Percentage Gain on 9/11
Via Investor Brand Network
Crinetics Pharma's Investigational Candidate Shows Promise In Rare Type Of Hormonal Disorder
On Sunday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) said its Phase 3 PATHFNDR-1 study evaluating paltusotine met the primary and secondary  
Via Benzinga
Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 71%
The company is working on a treatment for a growth hormone disorder. 
Via Investor's Business Daily
US Stocks Open Higher; Dow Jumps 150 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.46% to 34,736.26 while the NASDAQ rose 0.94% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
9 Analysts Have This to Say About Crinetics Pharmaceuticals
Via Benzinga
Analyst Expectations for Crinetics Pharmaceuticals's Future
Via Benzinga
Why Is Nuwellis (NUWE) Stock Down Today?
Nuwellis (NUWE) stock is taking a beating on Monday despite a lack of news or increased trading activity for the medical device company. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Tenon Medical (TNON) Stock Down 30% Today?
Tenon Medical (TNON) stock is falling on Monday after the surgical implant company announced a proposed public offering for its shares. 
Via InvestorPlace
Why Is Versus Systems (VS) Stock Up 17% Today?
Versus Systems (VS) stock is rising higher on Monday as the business software company's shares experience heavy trading this morning. 
Via InvestorPlace
Why Tenon Medical Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Where Crinetics Pharmaceuticals Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Crinetics Pharmaceuticals
Via Benzinga
Why Is Crinetics Pharmaceuticals (CRNX) Stock Up 64% Today?
Crinetics Pharmaceuticals (CRNX) stock is on the rise Monday after the company announced positive clinical trial results. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the workweek right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment, Says Analyst
Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
Via Benzinga
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics to Highlight Broad Pipeline at ENDO 2023
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship 
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.